Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/S1470-2045(07)70344-3 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Complete response of gallbladder cancer treated with gemcitabine and cisplatin chemotherapy combined with durvalumab: A case report and review of literature.
World J Gastrointest Oncol
January 2025
Department of Hepatobiliary Surgery, The First Affiliated Hospital of Chongqing Medical University, Chongqing 400016, China.
Background: Gallbladder cancer (GBC) is the most common and aggressive subtype of biliary tract cancer (BTC) and has a poor prognosis. A newly developed regimen of gemcitabine, cisplatin, and durvalumab shows promise for the treatment of advanced BTC. However, the efficacy of this treatment for GBC remains unclear.
View Article and Find Full Text PDFPica in childhood: Prevalence and developmental comorbidity.
Front Child Adolesc Psychiatry
February 2023
Faculty of Medicine, Institute of Clinical Medicine, Clinic of Psychiatry, Vilnius University, Vilnius, Lithuania.
Background: Pica is an eating disorder in which a person feels the urge to eat non-nutritious, non-food substances. It can occur at any age; however, a higher prevalence is observed among children with mental health issues and pregnant women. Recently, additional attention has been given to the role of sensory sensitivity in eating disorders.
View Article and Find Full Text PDFPoint prevalence survey on antibiotic use in the hospitals of Mauritius.
Front Antibiot
January 2023
Surveillance Epidemiologiques et Gestion des Alertes (SEGA), One Health network, Ebene, Mauritius.
Background: This study aims at determining the antibiotic prescribing pattern in admitted patients in the regional public hospitals of Mauritius.
Methods: A Point Prevalence Survey (PPS) on antibiotic use according to the World Health Organization Methodology for PPS on antibiotic use in hospitals, was carried out in 3 secondary public hospitals. Data was collected in February 2018 for Hospital 1 and in April-May 2019 for Hospital 2 and Hospital 3.
Pathological complete response following neoadjuvant chemotherapy with PD-1 inhibitor for locally advanced pancreatic cancer: case report.
J Gastrointest Oncol
December 2024
Department of Biliary-Pancreatic Surgery, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
Background: In recent years, the incidence of pancreatic cancer has shown an obvious increasing trend worldwide and even causes a greater disease burden to the mankind. Due to the lack of effective early surveillance methods, patients are often in the middle to advanced stages of their disease at the time of detection, thus losing the opportunity for surgery. The currently available chemotherapy regimens are yet to be further improved to prolong patient survival.
View Article and Find Full Text PDFBalancing anticancer therapy efficacy and safety in advanced hepatocellular carcinoma: a case report.
J Gastrointest Oncol
December 2024
Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Background: Hepatocellular carcinoma (HCC) is a significant health problem associated with several risk factors, increasingly driven by non-alcoholic steatohepatitis and metabolic syndrome. This association poses a challenge for the primary treatments of HCC, which may include immune checkpoint inhibitors and vascular endothelial growth factor inhibitors, due to their potential cardiotoxic effect. Therefore, it is imperative to balance the therapeutic effects of these agents with their potential cardiovascular adverse events.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!